Chemometec — December 2021
-
-
Jeg har tidligere set dig forudsige kursen "om tre dage" nærmest lige i øjet, og jeg har undret mig. "Hvordan fanden kan han det?" Men det er klart, at vi for nuværende er i "ragnarok" på så mange parametre, at det ikke er muligt. Jeg er dog stædigt tro mod Chemm på lang sigt. Vi må iføre os vores tålmodighedskappe - og trække vejret dybt. Så har jeg megen tillid til projektet.
-
Stillingsopslag fra hjemmesiden: Talent Acquisition Specialist at ChemoMetec US
You will play a key role in increasing our workforce to prepare us for our next stage of growth. Our goal is to expand in the US by 50% and you will be instrumental in helping us achieve this.
The ideal candidate will want to develop with our rapidly growing company and gain experience in working for a global leading biotech that has a small company feel. -
-
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
-
Chemometec rykker en klasse op i aktiesegment, da aktien fra 3. januar rykkes fra Midcap-segmentet til Large Cap-segmentet.
Det oplyser selskabet i en meddelelse.Large Cap-segmentet består af virksomheder, hvis markedsværdi overstiger 1 mia. euro. Chemometecs markedsværdi udgør i dag cirka 14 mia. kr.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind